Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound docetaxel (HB1801) phase 1 study in advanced solid tumors
NCT04471675Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of albumin-bound docetaxel in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Number of participants who experienced AE during cycle1 at 21 days, Number of participants who experienced Dose-Limiting Toxicity (DLT) during cycle1 at 21 days and 2 more. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04471675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471675.